本文關(guān)鍵詞： Technivie ombitasvir paritaprevir 基因型丙型肝炎病毒　出處：《臨床藥物治療雜志》2016年03期 　論文類型：期刊論文

【摘要】：Technivie由美國AbbVie制藥公司研發(fā),2014年FDA授予其突破性藥物資格,并通過優(yōu)先審查程序進(jìn)行了審批,于2015年7月24日上市。該藥由ombitasvir、paritaprevir、ritonavir復(fù)配而成,可直接口服給藥。Technivie與利巴韋林合用是世界上首個無需使用干擾素的基因型4丙型肝炎治療方案,它的出現(xiàn)使臨床上基因型4丙肝的治療產(chǎn)生了重大變化。筆者就Technivie的基本性質(zhì)、作用機制、藥動學(xué)、藥效學(xué)、臨床試驗及應(yīng)用等研發(fā)動態(tài)作一綜述,以期能為醫(yī)院臨床用藥起到指導(dǎo)作用。
[Abstract]:Technivie was developed by AbbVie Pharmaceuticals in the United States. In 2014, FDA awarded it a breakthrough drug qualification, which was approved through a priority review process and went on sale on July 24th 2015. The drug was prepared by a combination of ombitas virus paritaprevirr and ritonavir. The combination of ribavirin and .Technivie is the first genotypic hepatitis C therapy without interferon in the world. The research and development of mechanism, pharmacokinetics, pharmacodynamics, clinical trials and applications were reviewed in order to provide guidance for clinical use of drugs in hospitals.
【作者單位】： 國家應(yīng)急防控藥物工程技術(shù)研究中心軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所;
【分類號】：R512.63
，

本文編號：1503525